Description
Springer Drug Management of Prostate Cancer 1st Editon 2010 Hardbound by William D. Figg, Cindy H. Chau, Eric J. Small
Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges’ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials. Cell Biology of Prostate Cancer and Molecular Targets.- Cell Biology of Prostate Cancer and Molecular Targets.- Hormone Therapy.- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer.- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer.- Androgens and Prostate Cancer.- Androgen Receptor Biology in Prostate Cancer.- Androgen Receptor Antagonists.- 5-Alpha Reductase Inhibitors in Prostate Cancer.- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer.- Androgen Deprivation Therapy.- Pharmacogenetics of the Androgen Metabolic Pathway.- Chemotherapy.- Mitoxantrone.- Docetaxel.- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer.- Platinum Agents in Prostate Cancer.- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer.- Microtubule Targeting Agents.- Angiogenesis.- Principles of Antiangiogenic Therapy.- Bevacizumab in Advanced Prostate Cancer.- Thalidomide and Analogs.- Investigational Angiogenesis Inhibitors.- Pharmacogenetics of Angiogenesis.- Bone Metastasis.- Pathophysiology of Prostate Cancer Bone Metastasis.- Radiopharmaceuticals.- Bisphosphonates for Prevention and Treatment of Bone Metastases.- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer.- Calcitriol and Vitamin D Analogs.- Immunotherapy.- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches.- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer.- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX.- CTLA-4 Blockade for Prostate Cancer Treatment.- Prevention.- Prostate Cancer Chemoprevention Strategies.- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk.- Inflammation as a Target in Prostate Cancer.- Drug Development.- Challenges for the Development of New Agents in Prostate Cancer.- FDA Approval of Prostate Cancer Treatments.- Applications of Proteomics in Prostate Cancer.- Erratum to: Docetaxel.- Erratum to: Docetaxel.